Cytosorbents Crp receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Cytosorbents Crp (CTSO)
Assess today's live Cytosorbents Crp (CTSO) share price, performance and insights using our live NASDAQ: CTSO stock exchange data.
Analyse the historical data and Cytosorbents Crp share price performance charts on this page. Our technical summary section provides analysis on Cytosorbents Crp share price buy/sell indicators using real-time data (or discuss the Cytosorbents Crp (CTSO) stock price today with other investors in the Cytosorbents Crp NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CTSO share price (ISIN: US23283X2062) to enhance your trading decisions with our free investment tools and resources.
What Is the Cytosorbents Crp Share Price Today?
The Cytosorbents Crp share price today is 0.700.
What Is the Stock Symbol for Cytosorbents Crp
The stock symbol (or 'ticker') for Cytosorbents Crp is "CTSO."
What Stock Exchange Does Cytosorbents Crp Trade On?
Cytosorbents Crp is listed and trades on the NASDAQ stock exchange.
Is Cytosorbents Crp a Good Stock to Buy?
Determining whether Cytosorbents Crp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Cytosorbents Crp share price performance charts on this page. Our technical summary section provides analysis on Cytosorbents Crp share price buy/sell indicators using real-time data (or discuss the Cytosorbents Crp (CTSO) stock price today with other investors in the Cytosorbents Crp NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ CTSO share price (ISIN: US23283X2062) to enhance your trading decisions with our free investment tools and resources.
What Is the Cytosorbents Crp Share Price Today?
The Cytosorbents Crp share price today is 0.700.
What Is the Stock Symbol for Cytosorbents Crp
The stock symbol (or 'ticker') for Cytosorbents Crp is "CTSO."
What Stock Exchange Does Cytosorbents Crp Trade On?
Cytosorbents Crp is listed and trades on the NASDAQ stock exchange.
Is Cytosorbents Crp a Good Stock to Buy?
Determining whether Cytosorbents Crp—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.687
0.740
52 wk Range
0.600
1.610
CTSO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.6870.740
52 wk Range
0.6001.610
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
CTSO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
4.917
Upside
+602.38%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Significant return over the last week
- Form 8K Cytosorbents Crp For: 13 November
- Investing.com
- Cytosorbents Crp receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 8K Cytosorbents Crp For: 13 November
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy
Cytosorbents Crp Company Profile
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. The company’s flagship product is CytoSorb, an extracorporeal blood purification cartridge for the treatment of massive inflammation, organ failure, cardiothoracic surgery to remove antithrombotic drugs and inflammatory mediators that can lead to postoperative complications, such as severe bleeding, shock, failure to wean from mechanical ventilation, sepsis, and multiple organ failure; DrugSorb-ATR, an antithrombotic removal system; VetResQ, a broad-spectrum blood purification adsorber for the treatment of septic shock, toxic shock syndrome, toxin-mediated diseases, pancreatitis, trauma, liver failure, heat stroke, and lung injury in animals; PuriFi, an advanced hemoperfusion pump for blood purification therapies; and ECOS-300CY, an ex vivo organ perfusion system to preserve or improve the health and quality of harvested solid organs to be transplanted. In addition, it develops HemoDefend-BGA, a blood purification technology platform to reduce anti-A and anti-B antibodies in plasma and whole blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.
Cytosorbents Crp Earnings Call Summary for Q3/2025
- CytoSorbents Q3 2025 reported $0.04 loss per share, beating $0.05 forecast, with revenue up 10% YoY to $9.5M despite missing $10.4M target; stock rose 4.16% after hours.
- Gross margin improved to 70% from 61% in Q3 2024, with distributor sales up 14% and direct sales outside Germany up 24%, though German sales declined 3%.
- Company targets cash flow break-even by Q1 2026 and plans FDA pre-submission meeting for DrugSorb ATR in late 2025/early 2026, with regulatory decision expected mid-2026.
- Strategic restructuring of German sales team and company-wide cost reductions underway to improve financial health and operational execution.
- Cash position stands at $9.1M as of September 30, 2025, with CEO highlighting 'proven international business generating $37M in annualized high-margin product sales.'
Last Updated: 13/11/2025, 22:28
Read Full TranscriptCompare CTSO to Peers and Sector
Metrics to compare | CTSO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCTSOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −4.3x | −3.8x | −0.6x | |
PEG Ratio | −0.08 | −0.01 | 0.00 | |
Price/Book | 4.9x | 3.9x | 2.6x | |
Price / LTM Sales | 1.2x | 3.6x | 3.2x | |
Upside (Analyst Target) | - | 51.1% | 41.8% | |
Fair Value Upside | Unlock | 11.8% | 5.1% | Unlock |
Analyst Ratings
1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 4.917
(+602.38% Upside)
Earnings
Latest Release
Nov 13, 2025
EPS / Forecast
-0.04 / -0.05
Revenue / Forecast
9.50M / 10.40M
People Also Watch
FAQ
What Is the Cytosorbents Crp (CTSO) Share Price Today?
The live Cytosorbents Crp share price today is 0.700
What Stock Exchange Does Cytosorbents Crp (CTSO) Trade On?
Cytosorbents Crp is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Cytosorbents Crp?
The stock symbol (also called a 'ticker') for Cytosorbents Crp is "CTSO."
What Is the Current Cytosorbents Crp Market Cap?
As of today, Cytosorbents Crp market capitalisation is 43.96M.
What Is Cytosorbents Crp's (CTSO) Earnings Per Share (TTM)?
The Cytosorbents Crp EPS is currently -0.17 (Trailing Twelve Months).
When Is the Next Cytosorbents Crp Earnings Date?
Cytosorbents Crp's next earnings report will be released on 05 Mar 2026.
Is CTSO a Buy or Sell From a Technical Analyst Perspective?
Based on today's Cytosorbents Crp moving averages and other technical indicators, the daily buy/sell signal is Sell.
How Many Times Has Cytosorbents Crp Stock Split?
Cytosorbents Crp has split 1 times. (See the CTSO stock split history page for full effective split date and price information.)
How Many Employees Does Cytosorbents Crp Have?
Cytosorbents Crp has 149 employees.
What is the current trading status of Cytosorbents Crp (CTSO)?
As of 24 Dec 2025, Cytosorbents Crp (CTSO) is trading at a price of 0.700, with a previous close of 0.700. The stock has fluctuated within a day range of 0.687 to 0.740, while its 52-week range spans from 0.600 to 1.610.
What Is Cytosorbents Crp (CTSO) Price Target According to Analysts?
The average 12-month price target for Cytosorbents Crp is USD4.91667, with a high estimate of USD10 and a low estimate of USD0.75. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +602.38% Upside potential.
What Is the CTSO After Hours Price?
CTSO's last after hours stock price is 0.686, the stock has decreased by -0.014, or -2.000%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.